Literature DB >> 22287300

Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results.

Millie D Long1, Michael D Kappelman, Christopher F Martin, James D Lewis, Lloyd Mayer, Patricia M Kinneer, Robert S Sandler.   

Abstract

BACKGROUND: The widespread use of the Internet allows for unique research opportunities. We aimed to develop and follow an Internet-based cohort (e-cohort) of patients with self-reported inflammatory bowel diseases (IBD) over time.
METHODS: We established an e-cohort of adults with IBD (CCFA Partners) by recruiting through Crohn's and Colitis Foundation of America (CCFA) email rosters, CCFA Website promotion, social media, and other publicity mechanisms. The baseline survey included modules on disease course and activity, diet and exercise, and patient-reported outcomes (PROs). Baseline characteristics of the cohort are summarized using descriptive statistics.
RESULTS: A total of 7819 adults with IBD joined CCFA Partners through August, 2011. The median age was 42 years (interquartile range [IQR] 30-54), 5074 (72.3%) were female. A total of 4933 (63.1%) had Crohn's disease (CD), 2675 (34.2%) had ulcerative colitis (UC), and 211 (2.7%) had IBD unspecified. For CD, the mean short CD Activity Index (CDAI) was 151.9 (standard deviation [SD] 106.4), with 2274 (59.4%) in remission. For UC, the mean simple clinical colitis activity index (SCCAI) was 3.6 (SD 2.8), with 937 (42.9%) in remission. The mean short IBD questionnaire (SIBDQ) score was 48.7 (SD 11.8). SIBDQ was inversely correlated with disease activity (P < 0.01). The mean Morisky medication adherence score (MMAS) was 5.7 (SD 2.0). MMAS scores were inversely correlated with disease activity (P < 0.01).
CONCLUSIONS: CCFA Partners is a novel e-cohort. Enrollment is ongoing, with surveys twice yearly. CCFA Partners represents a unique resource to study PROs and changes in disease management over time.
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22287300     DOI: 10.1002/ibd.22895

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  53 in total

1.  Role of Nonsteroidal Anti-Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease.

Authors:  Millie D Long; Michael D Kappelman; Christopher F Martin; Wenli Chen; Kristen Anton; Robert S Sandler
Journal:  J Clin Gastroenterol       Date:  2016-02       Impact factor: 3.062

2.  Exercise decreases risk of future active disease in patients with inflammatory bowel disease in remission.

Authors:  Patricia D Jones; Michael D Kappelman; Christopher F Martin; Wenli Chen; Robert S Sandler; Millie D Long
Journal:  Inflamm Bowel Dis       Date:  2015-05       Impact factor: 5.325

3.  Harnessing person-generated health data to accelerate patient-centered outcomes research: the Crohn's and Colitis Foundation of America PCORnet Patient Powered Research Network (CCFA Partners).

Authors:  Arlene E Chung; Robert S Sandler; Millie D Long; Sean Ahrens; Jessica L Burris; Christopher F Martin; Kristen Anton; Amber Robb; Thomas P Caruso; Elizabeth L Jaeger; Wenli Chen; Marshall Clark; Kelly Myers; Angela Dobes; Michael D Kappelman
Journal:  J Am Med Inform Assoc       Date:  2016-01-28       Impact factor: 4.497

4.  Paternal Disease Activity Is Associated With Difficulty in Conception Among Men With Inflammatory Bowel Diseases.

Authors:  Ashwin N Ananthakrishnan; Christopher Martin; Sunanda Kane; Robert S Sandler; Millie D Long
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-11       Impact factor: 11.382

5.  Pouch-Related Symptoms and Quality of Life in Patients with Ileal Pouch-Anal Anastomosis.

Authors:  Edward L Barnes; Hans H Herfarth; Robert S Sandler; Wenli Chen; Elizabeth Jaeger; Van M Nguyen; Amber R Robb; Michael D Kappelman; Christopher F Martin; Millie D Long
Journal:  Inflamm Bowel Dis       Date:  2017-07       Impact factor: 5.325

Review 6.  Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.

Authors:  Millie D Long; Susan Hutfless; Michael D Kappelman; Hamed Khalili; Gilaad G Kaplan; Charles N Bernstein; Jean Frederic Colombel; Corinne Gower-Rousseau; Lisa Herrinton; Fernando Velayos; Edward V Loftus; Geoffrey C Nguyen; Ashwin N Ananthakrishnan; Amnon Sonnenberg; Andrew Chan; Robert S Sandler; Ashish Atreja; Samir A Shah; Kenneth J Rothman; Neal S Leleiko; Renee Bright; Paolo Boffetta; Kelly D Myers; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

7.  Perceptions of patients with inflammatory bowel diseases on biobanking.

Authors:  Millie D Long; R Jean Cadigan; Suzanne F Cook; Kaaren Haldeman; Kriste Kuczynski; Robert S Sandler; Christopher F Martin; Wenli Chen; Michael D Kappelman
Journal:  Inflamm Bowel Dis       Date:  2015-01       Impact factor: 5.325

8.  The Impact of Ostomy on Quality of Life and Functional Status of Crohn's Disease Patients.

Authors:  Maisa I Abdalla; Robert S Sandler; Michael D Kappelman; Christopher F Martin; Wenli Chen; Kristen Anton; Millie D Long
Journal:  Inflamm Bowel Dis       Date:  2016-11       Impact factor: 5.325

9.  Variation in Care of Inflammatory Bowel Diseases Patients in Crohn's and Colitis Foundation of America Partners: Role of Gastroenterologist Practice Setting in Disease Outcomes and Quality Process Measures.

Authors:  Kimberly N Weaver; Michael D Kappelman; Robert S Sandler; Christopher F Martin; Wenli Chen; Kristen Anton; Millie D Long
Journal:  Inflamm Bowel Dis       Date:  2016-11       Impact factor: 5.325

10.  Evaluation of Gastrointestinal Patient Reported Outcomes Measurement Information System (GI-PROMIS) Symptom Scales in Subjects With Inflammatory Bowel Diseases.

Authors:  Bharati Kochar; Christopher F Martin; Michael D Kappelman; Brennan M Spiegel; Wenli Chen; Robert S Sandler; Millie D Long
Journal:  Am J Gastroenterol       Date:  2017-08-29       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.